The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
 
Maria Ignez Braghiroli
No Relationships to Disclose
 
Maria Fernanda Batistuzzo Vicentini
Employment - BMS Brazil
Travel, Accommodations, Expenses - BMS Brazil
 
Leonardo Gomes da Fonseca
No Relationships to Disclose
 
Karla Teixeira Souza
No Relationships to Disclose
 
Renata Colombo Bonadio
No Relationships to Disclose
 
Oddone Freitas Melro Braghiroli
No Relationships to Disclose
 
Maria Cecília Machado Mathias
No Relationships to Disclose
 
Aley Talans
No Relationships to Disclose
 
Maria Elizabeth Zambrano Mendoza
No Relationships to Disclose
 
Juliana Goes Martins
No Relationships to Disclose
 
Jorge Sabagga
No Relationships to Disclose
 
Camila Venchiarutti Motta Venchiarutti Moniz
No Relationships to Disclose
 
Paulo Marcelo Hoff
Leadership - Oncologia D’Or
Stock and Other Ownership Interests - Oncostar
Honoraria - Bayer Health (I); United medical (I)
Consulting or Advisory Role - Bayer (I); Exelixis (I); Lilly (I); United Health Group (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Exelixis (Inst); Lilly (I); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst)